Verastem - Turnaroundspekulation 2016

die letzten Tage.
Baker Bros. haben sich mit 10,144,039 shares eingedeckt.

https://fintel.io/so/us/vstm  

CHMP recommends five new drugs, gives advice on Celltrion COVID antibody

... European Medicines Agency?s (EMA) Committee for Medicinal Products for Human Use (CHMP) on Friday issued positive opinions for five new medicines and six extensions of therapeutic indications following its meeting earlier this week.

The newly recommended medicines include Verastem?s Copiktra (duvelisib) to treat relapsed or refractory chronic lymphocytic leukemia and refractory follicular lymphoma and Janssen-Cilag?s multiple sclerosis treatment Ponvory (ponesimod). The committee also recommended two oral contraceptives with the same active substances, Gedeon Richter?s Drovelis (estetrol/drospirenone), Estetra SPRL?s Lydisilka (estetrol/drospirenone), and Diurnal Europe BV?s hybrid medicine Efmody (hydrocortisone) for patients 12 and older with congenital adrenal hyperplasia (CAH)....

https://www.raps.org/news-and-articles/...w-drugs-gives-advice-on-cel  

 

 

 

 

 

endlich loszugehen:

http://ih.advfn.com/...p;width=800&vol=1&height=400&Vol=1  

Untypisches hohes Volumen!

https://www.marketwatch.com/investing/stock/vstm?mod=over_search  

H.C. Wainwright analyst Sean Lee CFA maintained a Buy rating on Verastem (VSTM) today and set a price target of $4.00. The company?s shares closed last Wednesday at $2.80.

https://www.smarteranalyst.com/new-blurbs/...buy-from-h-c-wainwright/  

Haben ihren Anteil erhöht, halten aktuell nun 18.685.695 Mio. Shares!  

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Results of Early Trial Demonstrate 70% Overall Response Rate (ORR) in Patients with KRAS Mutant Tumors, 44% ORR in KRAS Wild-Type Tumors and 52% ORR in All Evaluable Patients with a Favorable Safety Profile

https://investor.verastem.com/news-releases/...herapy-designation-vs/  

https://www.marketbeat.com/stocks/NASDAQ/VSTM/price-target/  

schön langsam und stetig!  

Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer

https://www.businesswire.com/news/home/20210920005200/en/  

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

?Median progression-free survival (mPFS) across all patients treated with VS-6766 in combination with defactinib in the study is 23.0 months.

?11 of 24 (46%) patients treated with the combination achieved a confirmed partial response (PR). Of the 11 patients with KRAS mutant LGSOC, 7 (64%) achieved a confirmed PR.

?Combination continues to exhibit a favorable tolerability profile.

?Top-line results from the selection portion of Verastem?s registration-directed Phase 2 RAMP 201 LGSOC study expected during the first half of 2022.

https://finance.yahoo.com/news/...updated-investigator-153000366.html  

Einige Insiderverkäufe in den letzten Tagen! Steckt mehr dahinter?
https://investor.verastem.com/financial-information/sec-filings  

Danke für Hinweis!
Wird langsam Zeit das der Zug hier ins Rollen kommt.  

1/06/2022 BVF PARTNERS LP  Bought 3.5 Million shares of Verastem Inc


https://money.cnn.com/quote/quote.html?symb=VSTM  

MK 305 Mio. $, operative Ausgaben pro Quartal ~15 Mio. $. Cashbestand von 103 Mio. $ soll bis 2024 reichen. Nehme ich mal in Beobachtung.
https://investor.verastem.com/news-releases/...2021-financial-results  

Mk 208 Mio. $, bei 0,60$ denke ich über einen Einstieg nach  

Zahlen für Q4/21

• Umsatz 0,5 Mio. $
  
• Verlust 16,5 Mio. $
  
• Cash 100 Mio. $
  
• MK 234 Mio. $
  

-  Company Secures up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC;

- Expected Cash Runway Through 2025 to Support Continued Development and Potential Commercial Launches of VS-6766 and Defactinib

- Enrollment Complete in Selection Phase (Part A) of RAMP 201 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer; Expect to Report Results from Part A in 2Q 2022

- Enrollment Complete in Selection Phase (Part A) of RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of KRAS G12V Mutant Non-Small Cell Lung Cancer; Expect to Report Results from Part A in 2H 2022

https://investor.verastem.com/news-releases/...ter-and-full-year-2021

Durch das Funding mit Oxford wird VSTM wieder interessanter, beobachte ich weiter, Alert bei 1,00$

 

ohne News

https://ih.advfn.com/...;width=800&vol=1&height=400&Vol=1  

RBC Capital Initiates Coverage On Verastem with Outperform Rating, Announces Price Target of $5

https://www.benzinga.com/news/22/04/26628716/...ces-price-target-of-5
 

MK 194 Mio. $, bei Cash+Finanzierung = 250 Mio. $, dazu eine gute Reichweite und noch ein paar Katalysatoren in 2022